Respiratory Syncytial Virus Immunoreactivity, Vaccine Development, and Therapeutics

Elawar, Farah; Götte, Matthias; Lee, Nelson; Fearns, Rachel; Marchant, David

doi:10.1002/9783527810697.ch4

Cited by 1 publication

(1 citation statement)

References 184 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Targeting inflammatory molecules/anti-inflammatory molecules Danirixin (GSK1325756) RV568, (narrow spectrum kinase inhibitor) [ 20 , 21 , 27 , 50 , 51 , 54 , 58 , 79 ], 7. Prophylactics and immunoregulators MEDI 557 (recombinant human monoclonal antibody) MEDI 8897 (human RSV monoclonal antibody) RI-001 (polyclonal antibody) Motavizumab (MEDI-524), derived from palivizumab Trivalent nanobody ALX-0171 D25 RSV antibody (against F glycoproteins) (RSV-IVIG, RespiGam) intravenous immunoglobulin Palivizumab (humanized monoclonal IgG1 antibody) ALX-0171 (a nanobody preparation) REGN2222, (human monoclonal IgG1 antibody against RSV-F) MEDI-557 (derived from motavizumab) MEDI-8897, derived from D25-, an anti-RSV F MAb) [ 106 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 ] …”

Section: Main Bodymentioning

confidence: 99%

Respiratory Syncytial Virus Infection: Treatments and Clinical Management

Malik¹,

Ahmad

Muhammad

et al. 2023

Vaccines

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a major healthcare concern, especially for immune-compromised individuals and infants below 5 years of age. Worldwide, it is known to be associated with incidences of morbidity and mortality in infants. Despite the seriousness of the issue and continuous rigorous scientific efforts, no approved vaccine or available drug is fully effective against RSV. The purpose of this review article is to provide insights into the past and ongoing efforts for securing effective vaccines and therapeutics against RSV. The readers will be able to confer the mechanism of existing therapies and the loopholes that need to be overcome for future therapeutic development against RSV. A methodological approach was applied to collect the latest data and updated results regarding therapeutics and vaccine development against RSV. We outline the latest throughput vaccination technologies and prophylactic development efforts linked with RSV. A range of vaccination approaches with the already available vaccine (with limited use) and those undergoing trials are included. Moreover, important drug regimens used alone or in conjugation with adjuvants or vaccines are also briefly discussed. After reading this article, the audience will be able to understand the current standing of clinical management in the form of the vaccine, prophylactic, and therapeutic candidates against RSV. An understanding of the biological behavior acting as a reason behind the lack of effective therapeutics against RSV will also be developed. The literature indicates a need to overcome the limitations attached to RSV clinical management, drugs, and vaccine development that could be explained by dealing with the challenges of current study designs with continuous improvement and further work and approval on novel therapeutic applications.

show abstract